Lowers the risk of stroke and systemic embolism. ANDA 208040, held by Alkem Labs Ltd. Dabigatran Etexilate Mesylate.
As of Nov 16, 2026, ANDA 208040 (Dabigatran Etexilate Mesylate), held by Alkem Labs Ltd, was first approved by FDA on Sep 11, 2024, with 2 approved supplements and 0 published complete response letters.
Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery 1.
| Sep 11, 2024 | Original application | Approved | None posted |
| Mar 11, 2020 | Original application | Approved |
| Dabigatran Etexilate MesylateEQ 75MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 150MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Dabigatran Etexilate MesylateEQ 110MG BASE · capsule;oral | Dabigatran Etexilate Mesylate | Rx |
| Sep 11, 2024 | Original application | Approved | None posted |
| Aug 16, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 16, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Mar 11, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters